



SGN-CD228A

An investigational antibody–drug conjugate directed to CD228

Anti-CD228 monoclonal antibody


Humanized monoclonal antibody monoclonal that binds to CD228

PEGylated β -glucuronidase linker

Covalently attaches an average of 8 MMAE molecules to the antibody and releases agent within the target cell

MMAE

Microtubule-disrupting agent



Target: CD228

- Cell surface GPI-anchored glycoprotein that belongs to the transferrin superfamily¹
- Expressed in mesothelioma, NSCLC, breast, colorectal, and pancreatic carcinomas^{1,2}
- Limited expression in normal tissues^{1,2}

Proposed Mechanism of Action^{3-6,a}

- Preferential release of MMAE within target cells and subsequent apoptosis
- Bystander effect
- Induction of immunogenic cell death

GPI: glycosylphosphatidylinositol; **MMAE:** monomethyl auristatin E; **NSCLC:** non–small cell lung cancer

^a Based on preclinical data.


1. Sandall SL, et al. *Cancer Res.* 2019;79(Suppl 13):Abstract 2688. 2. Patnaik A, et al. *J Clin Oncol.* 2020;38(Suppl 15):TPS3652. 3. Sandall S, et al. Abstract presented at: AACR; Apr 2019; Atlanta, GA. Abstract 3832. 4. Sandall S, et al. Abstract presented at: AACR; Jun 2020; Virtual. Abstract 6092. 5. Burton JK, et al. *AAPS J.* 2019;22 :12. 6. Cao A, et al. *Cancer Res.* 2016;76(Suppl 14):Abstract 4914.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.



Proposed Mechanism of Action^{1-4,a}

- 1 Binds to CD228
- 2 Complex is internalized and traffics to the lysosome
- 3 MMAE is released
- 4 Microtubule disruption
- 5 Cell cycle arrest and apoptosis



MMAE: monomethyl auristatin E

^a Based on preclinical data.

1. Sandall S, et al. Abstract presented at: AACR; Mar 2019; Atlanta, GA. Abstract 3832. 2. Sandall S, et al. Abstract presented at: AACR; Jun 2020; Virtual. Abstract 6092. 3. Burton JK, et al. AAPS J. 2019;22:12. 4. Cao A, et al. Cancer Res. 2016;76(Suppl 14):Abstract 4914.

Clinical Trials



RECRUITING

SGN228-001: Advanced solid tumors (NCT04042480) SGN-CD228A

Phase 1

Phase 2

Phase 3

Clinical trial information retrieved from clinicaltrials.gov, accessed October 2022.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Seagen and its logo are US registered trademarks of Seagen Inc. Other trademarks are property of their respective owners.

For more information, contact us at:
+1-855-4SEAGEN (+1-855-473-2436)
medinfo@seagen.com / medinfoEU@seagen.com
www.seagenmedinfo.com